

## Top Tier\* NExT Applications

From Academia			
Applicant Name	Institution	Project Title	Cycle
Bresnick, Anne R.	Albert Einstein College of Medicine	Development of S100A4 Inhibitors	1
Deshaies, Raymond	California Institute of Technology	Small Molecule Inhibitors of ATPase p97	1
Earp, H. Shelton	University of North Carolina-Chapel Hill	Developing Small Molecule Mer Inhibitor	1
Frangioni, John V.	Beth Israel Deaconess Medical Center	NIR Fluorophore for Image-guided Surgery	1
Grandis, Jennifer R.	University of Pittsburgh	Inhibitors of STAT3 Activation	1
Hsieh, James J.	Washington University-St. Louis Memorial Sloan Kettering Cancer Center	Optimization of Lead Small Molecule Inhibitors of Taspase 1 for Cancer Therapeutics	1
Vogelstein, Bert	Johns Hopkins University	MTAP Isogenic Drug Screen	1
Altieri, Dario C.	University of Massachusetts Medical School	Clinical Development of Mitochondria-targeted Hsp90 Antagonists, GAMITRINIBS	2
Dang, Chi	Johns Hopkins University School of Medicine	Development of FX11, a Lactate Dehydrogenase A (LDHA) Inhibitor, as an Anti-neoplastic Agent	2
Kufe, Donald W.	Dana-Farber Cancer Institute	The Development of a Novel Anti-cancer Agent Against the MUC1 Oncoprotein	2
Melnick, Ari	Joan & Sanford I Weill Medical College	Clinical Translation of a BCL-6 Inhibitor	2
Prochownik, Edward V.	Children's Hospital of Pittsburgh	Evaluation of Rationally-Designed Small Molecules Directed Against the c-Myc Oncoprotein	2
Roden, Richard B.	Johns Hopkins University	Production of an HPV16 L2E6E7 Vaccine with GPI-0100 Adjuvant for the Treatment of HPV-Associated Disease	2
Wickline, Samuel A.	Washington University	Design, Formulation, and Preclinical Development of Wortmannin Nanoparticles for Cancer Therapy	2
Biswal, Shyam	Johns Hopkins University	Development of NRF2 Inhibitors for Cancer Chemotherapy	3
Alvarez, Ronald	The University of Alabama at Birmingham	A Novel and High Potency Combination Treatment Using Ad5-Delta24RGD and Chemotherapy for Human Ovarian Cancer	4

Doemling, Alexander	University of Pittsburgh	p53/MDM4/MDM2 Antagonists	4
Mazar, Andrew Paul	Northwestern University - Evanston Campus	huATN-658, a Humanized Monoclonal Antibody Targeting the Urokinase Receptor	4
Rathmell, Wendy Kimryn	The University of North Carolina at Chapel Hill	Ror2 as a Target for Renal Carcinoma	4
Kirsch, David	Duke University Medical Center	Using Molecular Imaging to Detect Microscopic Residual Cancer During Surgery	5
Miller, Jeffrey	University of Minnesota - Twin Cities	rhIL-15 to Exploit NK Cells in Cancer Therapy	5
Sutcliffe, Julie	Regents of the University of California (University of California, Davis)	Targeted Imaging of alphavbeta6 with [18F]-peptides	5
Liu, Yang	University of Michigan	Development of Clinical Grade Echinomycin for Post-remission Therapy of AML	8
Rosenthal, Eben	The University of Alabama at Birmingham	Intraoperative Optical Imaging to Guide Surgical Resection of Cancer	8
Fu, Haian	Emory University	Targeting Oncogenic Protein-Protein Interactions for Therapeutic Discovery	9
Lieber, Michael	University of Southern California	Inhibitors of the Artemis Endonuclease for Cancer Chemotherapy	9
Heyer, Wolf-Dietrich	University of California (University of California Davis)	Inhibitors of Recombinational DNA Repair	10
Fesik, Stephen	Vanderbilt University Medical Center	Discovery of Subnanomolar Inhibitors of Mcl-1	11
Kaur, Balveen	The Ohio State University Research Foundation	Production and Safety Testing of 34.5ENVE, a Novel Oncolytic Virus	11
Wang, Qiming	University of Pittsburgh	Development of Protein Kinase D Inhibitors for Prostate Cancer Therapy	11
Fenical, William	The Regents of the University of California, Scripps Institution of Oceanography	Preclinical Development of the Seriniquinone Class of Melanoma-Selective Ag	12
Fenical, William	The Regents of the University of California, Scripps Institution of Oceanography	Discovery of Agents that Induce Autophagy	12
Yan, Qin	Yale University	Identifying Small Molecule Inhibitors of Histone Demethylases RBP2 and PLU1	12
Gromeier, Matthias	Duke University Medical Center	Acquisition of Bulk Substance (cGMP) PVS-RIPO for Extended Clinical Studies	13
Ravetch, Jeffrey	The Rockefeller University	Agonistic anti-CD40 Therapy Enhanced by FcgammaRIIB-targeted Fc-engineering	14

Parsons, Ramon	Icahn School of Medicine at Mount Sinai	Development of PTEN-Long for Cancer Therapy	15
Salvino, Joseph	Drexel University	Lead Optimization of a Potent CX3CR1 Antagonist	15
Gao, Jinming	UT Southwestern Medical Center	Production & Toxicology Evaluation of Nanoprobes for Fluo-guided Surgery	16
Zhang, Shuxing	University of Texas M.D. Anderson Cancer Center	Targeting Skp2 Ubiquitination for Advanced Prostate Cancer Therapy	17
Fesik, Stephen	Vanderbilt University Medical Center	Discovery of Small Molecule Inhibitors of the WDR5-MLL1 Interaction	18
Gray, Nathanael	Dana-Farber Cancer Institute	Development of PIP4K2 Inhibitors for the Treatment of p53 Deficient Cancers	18
Markowitz, Sanford	Case Western Reserve University	SW033291 Markedly Accelerates Tri-Lineage Recovery After Marrow Transplant	19
Gillanders, William	Washington University in St.Louis	Neoantigen Vaccine + anti-PDL1 Phase 1 Clinical Trial	21
Schwab, Matthias	Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology	Supplementation of TAMoxifen Standard Therapy with ENDOXifen	21
Lentzsch, Suzanne	The Trustees of Columbia University in the City of New York	A Phase II, Non-randomized Study of 11-1F4 Chimeric Monoclonal Antibody	22
Perera, Liyanage	National Cancer Institute, Center for Cancer Research, NIH	CARs Targeting the Chemokine Receptor CCR4 as a Therapeutic Modality for T	23
Dubinett, Steven	The Regents of the University of California, Los Angeles	Intratumoral Ad-CCL21-DC Combined with Intravenous anti-PD-1 for NSCLC	24
Vahdat, Linda	Joan & Sanford I. Weill Medical College of Cornell University	Phase 2 Randomized, Placebo-controlled Study of Tetrathiomolybdate in TNBC	24
Patz Jr., Edward	Duke University Medical Center	A Human Complement Factor H Antibody for the Treatment of Cancer	25
Conover, Cheryl	Mayo Clinic.	PAPP-A: A New Therapeutic Target for Ovarian Cancer	27
Heyer, Wolf-Dietrich	The Regents of the University of California (University of California Davis)	Targeting the ALT Pathway to Induce Synthetic Lethality	27
Lazo, John Stephen	University of Virginia School of Medicine	Small Molecule Targeting of the Oncogenic PTP4A3 Phosphatase	28
Sklar Ph.D., Larry A.	University of New Mexico HSC	Multiplex HTS for Small GTPases	28
Anand, Sudarshan	Oregon Health & Science University	TREX1 Inhibitors for Anti-tumor Immunity	29
Fesik, Stephen W.	Vanderbilt University	Discovery of Small Molecule, Direct Inhibitors of Oncogenic Wnt Signaling	29

Insel, Paul	University of California, San Diego - Health Sciences	Targeting GPR68 for PDAC	29
Lengyel, Ernst	The University of Chicago	Targeting the Stromal Epigenome with Small Molecule Inhibitors of NNMT	29
Jin, Rongsheng	The Regents of the University of California (Irvine)	Novel Small Molecule Inhibitors of Wnt Signaling	32
Marlowe, Timothy	Arizona Board of Regents, University of Arizona	Discovery of Fragment-based and Peptidic Inhibitors of the FAK FAT Domain	32
Muller, Dr. Florian	University of Texas M.D. Anderson Cancer Center	Collateral Lethality: Enolase Inhibition for Glioblastoma Tumors	32
Demetriou, Michael	The Regents of the University of California (Irvine)	Late Pre-clinical Development of GlyTR1 for Leptomeningeal Carcinomatosis	33
Fesik, Stephen W.	Vanderbilt University	Tissue Specific Degradation of BRD4 and BCL-XL using PROTACs	34
Kufe, Donald W.	Dana-Farber Cancer Institute	Targeting MUC1-C with an ADC for Treatment of Aggressive Recalcitrant Cance	34
Kufe, Donald W.	Dana-Farber Cancer Institute	Targeting MUC1-C for Imaging of Aggressive Recalcitrant Cancers	34
Ferrando, Adolfo	Columbia University Medical Center	Identification of NT5C2 Inhibitors for Reversal of Chemotherapy Resistance	35
Pattenden, Samantha	University of North Carolina at Chapel Hill	Development of a High Throughput Assay Based on Chromatin Accessibility	35
Farrell, Nick	Virginia Commonwealth University	Precision Medicine for Platinums	36
Guccione, Ernesto	Icahn School of Medicine at Mount Sinai	IND-enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1	36
Zhou, Pengbo	Joan & Sanford I. Weill Medical College of Cornell University	Ubiquitin Ligases as Targets for Cancer Therapy	36
Mackall, Crystal	Stanford University	GPC2 CAR T Cells for Children and Young Adults with NB & MB	37
Odunsi, Adekunle	The University of Chicago	Development of an Oncolytic Vaccinia Virus “Armed” with a CXCR4 Antagonist	37
Guengerich, Frederick	Vanderbilt University	Targeting Cytochrome b5 to Inhibit Androgen Synthesis in Prostate Cancer	37
Chen, Sidi	Yale University	Translating a Metabolic Enhancer CAR-T Towards IND-enabling Stage	39
Snook, Adam	Thomas Jefferson University	Lm-GUCY2C Manufacturing	39

## From Private Sector - Biotechnology Companies

Applicant Name	Institution	Project Title	Cycle
Leopold, Lance	Ascenta Therapeutics, Inc.	AT-406, a Pan, Oral IAP Inhibitor	1
Kovach, John S.	Lixte Biotechnology Holdings, Inc.	Novel Inhibitor of PP2A Potentiates Chemotherapy	2
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC105 as a Novel Antiangiogenic Monoclonal Antibody for Cancer Therapy	2
Davis, Thomas	Celldex Therapeutics, Inc.	Clinical Development of CDX-1308 Vaccine Regimen	3
Graham, Martin	Tetralogic Pharmaceuticals Corporation	Predictive Biomarkers of SMAC-Mimetic (TL32711) Efficacy in Ovarian Cancer	4
Paradiso, Linda J.	America Stem Cell, Inc	Accelerated Hematopoietic Recovery with ASC101	4
Roninson Porter, Igor	Senex Biotechnology, Inc.	Optimization and Testing of CDK3 Inhibitors	4
Frankel, Stanley	Micromet	Blinatumomab Clinical Development for B-lineage Malignancies	5
Hamdy, Ahmed	Pharmacyclics, Inc.	PCI-32765, Btk Inhibitor for B-cell Malignancies	5
Klein, Pamela	Intellikine, Inc.	INK128 a TORC1/2 Inhibitor in Solid Tumors and Hematologic Malignancies	6
Frye, John	Exelixis, Inc.	XL184 (cabozantinib)	7
Miller, Langdon	Calistoga Pharmaceuticals, Inc	CAL-101 for Patients with Neoplastic Diseases	7
Hergenrother, Paul	Vanquish Oncology, Inc.	Toward an IND Filing for Procaspace-3 Activating Compounds	8
Hussein, Mohamad	Celgene Corporation	Pomalidomide in Rare Diseases with Unmet Medical Needs	8
Leigh, Bryan	Tracon Pharmaceuticals	Development of TRC102 as a Novel Inhibitor of Base Excision Repair	8
Wagner, Anthony	Amgen Incorporated	Ganitumab (AMG 479) CRADA	8
Davis, Thomas	Celldex Therapeutics, Inc.	Clinical Development of CDX-1401 Vaccine Regimen	9
Leopold, Lance	Incyte Corporation	INCB024360, A Novel Orally-Administered IDO 1 Inhibitor for Cancer Treatment	9

Orton, Darren	StemSynergy Therapeutics, Inc	Development of a Wnt Inhibitor	9
Adams, Chris	Andarix Pharmaceuticals	Clinical Dev't of Rhenium188 P2045 for Systemic Radiotherapy of Lung Cancer	10
Hummersone, Marc	Pharminox Ltd	The Optimisation & Development of Telomere Targeted Agents for Cancer Therapy	10
Wolchok, Jedd	Memorial Sloan-Kettering Cancer Center	Manufacturing of a VRP-TRP2 Vaccine for a Phase I Clinical Trial	10
Tabakoff, Boris	Lohocla Research Corporation	Cancer and Cancer Therapy Induced Neuropathic Pain: Treatment Prevention	11
Dorr, Andrew	BioMarin Pharmaceutical Inc.	Patient Selection Assay Strategies to Predict Patients That Respond to PARP	12
Hergenrother, Paul	Vanquish Oncology, Inc.	Toward an IND Filing for Procaspace-3 Activating Compounds	13
Fields, Scott	Vertex Pharmaceuticals Inc	VX-970 a Novel ATR Inhibitor for Clinical Development in Cancer Patients	15
Fields, Scott	Vertex Pharmaceuticals Inc	VXc-984 a Novel DNA-PK Inhibitor for Development in Cancer Patients	15
Isaacman, Steven	Nanometics LLC	An Orally Available Therapeutic for Triple Negative Breast Cancer	15
Quackenbush, Elizabeth	Celldex Therapeutics, Inc.	Continued Development of the Antibody-drug Conjugate CDX-011	15
Tweardy, David	StemMed, Ltd.	Oral Stat3 Inhibitor	16
Allen, Andrew	Clovis Oncology, Inc.	Combination Therapies to Overcome CO-1686 Resistance in Mutant EGFR NSCLC	17
Brown, Bob	Dicerna Pharmaceuticals, Inc.	Efficacy of DCR-MYC in Patient-Derived Xenograft Models	17
Brown, Bob	Dicerna Pharmaceuticals, Inc.	$\beta$ -catenin/CTNNB1 DsiRNA LNP Therapeutic for HCC and CRC	17
Carpi, David	Targeted Therapy Technologies, LLC	Episcleral Antineoplastic Interventions for Pediatric Retinoblastoma	17
Davis, Thomas	Celldex Therapeutics, Inc.	Continued Development of the Varlilumab (CDX-1127)	17
Matthews, Bill	Leuchemix, Inc	Clinical and Manufacturing Support for LC-1	18
Holsapple, Earle	SciTech Development, LLC	NanoFenretinide Drug Products for Treating Mycosis Fungoides and its Leukem	19
Bedu-Addo, Frank	PDS Biotechnology Corporation	A Phase II Study to Evaluate the Efficacy and Safety of PDS0101	20

Keilhack, Heike	Epizyme Inc.	EZH2 Inhibitor Tazemetostat as Novel Cancer Therapy	20
Lehr, Martin	Context Therapeutics LLC	Lead Optimization of a Potent Sigma1 Inhibitor	20
Ortner, Mary	SolaranRx, Inc.	SolaranRx SRX-1177 for the Treatment of Metastatic Melanoma	20
Blakemore, Stephen	Epizyme Inc.	Pinometostat (EPZ-5676) NCI-CTEP Collaboration Proposal	21
Cox, Michael	Loxo Oncology, Inc.	Development of LOXO-101, a Pan TRK-inhibitor, in Hematologic Malignancies	21
Yen, Katharine	Agios Pharmaceuticals, Inc.	AG-881 in Rare IDH Mutant Solid Tumors	22
Gostissa, Monica	121 Bio, LLC (now Agenus)	Anti-PD-L1 PET Imaging Agents	23
Thacher, Scott M	Orphagen Pharmaceuticals, Inc	Small Molecule Antagonists of SF-1 for Treatment of Adrenocortical Cancer	23
Demo, Susan	Calithera Biosciences, Inc.	Targeting Tumor Metabolism with CB-839: A Novel Inhibitor of Glutaminase	24
Peng, Ben	XL Sci-Tech, Inc.	Image-Guided Radioembolization of Liver Tumors	24
Maeda, Dean Yoshimasa	Syntrix Biosystems, Inc.	cGMP Production of Small Molecule Immunotherapeutic SX-682	25
Proulx, Louise	Diazon Pharmaceuticals Inc.	DZ-2384 A Potent MTA w/ No Neurotoxicity at Effective Plasma Levels in Rats	27
Rittenhouse-Olson, Kate	For-Robin, Inc	hJAA-F11, a Humanized Anti-Thomsen Friedenreich Antibody for Cancer Therapy	27
Thackray, Helen	GlycoMimetics, Inc.	GMI-1271 - E-Selectin Antagonist for AML	27
Takimoto, Chris Hidemi Mizufune	Forty Seven, Incorporated	Novel Combination Regimens with Hu5F9-G4, an Anti-CD47 Monoclonal Antibody	28
Li, Yajuan	Molecular Theranostics, LLC	A Targeted MRI Contrast Agent for Differential Diagnosis of Prostate Cancer	29
BEN, YONG	BioAtla	BioAtla Conditionally Active Biologics (CABs) Collaboration with NCI	30
Bono, Francoise	Onxeo SA	AsiDNA: A DNA Repair Pathways Inhibitor / Decoy Strategy & Agonist Effect	30
Goldberg, Michael	STIMIT Corporation	Extended Release of Perioperative Immunotherapy Vastly Improves Outcomes	31
Plasse, Terry	Serene LLC	Tin-117m-DTPA for Prostate Cancer Bone Metastases	31

Eliseev, Alexey	Bipharm LLC	Development of Hec1/Nek2 Inhibitor Targeting Aneuploidy and Metastasis	33
Shah, Jatin	Karyopharm Therapeutics, Inc.	Selinexor for Unmet Needs in Glioblastoma Multiforme and Sarcomas	33
von Roemeling, Reinhard	Curis, Inc	CA-4948 IRAK4 Research Plan	34
Paralkar, Vishwas	Cybrexa, Inc	Cybrexa CBX-11 and CBX-12 Alphalex Technology	35
Moris, Francisco	EntreChem SL	EC-8042, a Mithralog for Pediatric Tumors with Transcriptional Deregulation	36
Rangwala, Reshma	Aravive, Inc	ABV-500, Harnessing the AXL/GAS6 Pathway	36
Yellin, Michael	Celldex Therapeutics Inc.	CDX-1140, a Unique Agonist Anti-CD40 mAb for Cancer Immunotherapy	36
Bruce Dezube Rege,	Alkermes Inc.	Nemvaleukin Alfa NExT Program Application	37
Wei, Michael	Genentech, Inc.	Genentech Mosunetuzumab NExT Application	37
Drake, Penelope	Redwood Bioscience Inc.	CAT-03-106, an Anti-CD25 Antibody-drug Conjugate with a Noncleavable Linker	37
Li, Bin	StemSynergy Therapeutics, Inc	Repurpose Pyrvinium as a Familial Adenomatous Polyposis (FAP) Therapy	37
Leopold, Judith	Mekanistic Therapeutics	Development of MTX-531: A Precision Combination Therapy Approach	38
Jarvelainen, Harri	Cend Therapeutics Inc.	CEND-1 Clinical and Translational Concept Application	38
Todd, Collin	SpringWorks Therapeutics, Inc.	Mirdametinib: Novel MEK Inhibitor with Best-In-Class Brain Penetration	38
Xaus, Jordi	Oryzon Genomics SA	Iadademstat, a LSD1 Inhibitor with Multiple Anti-tumor Therapeutic Application	38
Barry, Elly	Day One Biopharmaceuticals	DAY101 in RAF-activated Malignancies	39
Brockman, Michelle	Genentech, Inc.	Giredestrant NEXT Application	39
<b>From Government</b>			
<b>Applicant Name</b>	<b>Institution</b>	<b>Project Title</b>	<b>Cycle</b>
Waldmann, Thomas	National Cancer Institute, NIH NCI Center for Cancer Research	Anti-IL-15 Receptor Antibody Therapy of Celiac Disease Associated Lymphoma	3



Kalab, Petr	Center for Cancer Research, NCI, NIH	RanGTP Gradient-regulated Mechanisms as a Target of Cancer Chemotherapy	8
Choyke, Peter	National Cancer Institute, Center for Cancer Research, NIH	A Phase II Study of F-18 DCFBC, a Prostate Specific Membrane Antigen-Target	11
Griffiths, Gary	Center for Cancer Research, NCI, NIH	Large Scale Preparation of IR700-Panitumumab for Clinical Use	14
Marugan, Juan	National Center for Advancing Translational Sciences	Metarrestin, a New Approach Towards Metastasis	16
Harris, Curtis	National Cancer Institute, NIH NCI Division of Cancer Epidemiology and Genetics	Anti-miR-21 Therapeutics to Treat and Prevent Metastatic Colon Cancer	18
Leppla, Stephen	National Institute of Allergy and Infectious Diseases, NIH NIAID	Protease-activated Anthrax Toxin for Treatment of Human Solid Tumors	21
Hou, Steven	National Cancer Institute, Center for Cancer Research	An In vivo Large-scale Chemical Screening Using Drosophila for Anti-cancer	22
Nilubol, Naris	National Cancer Institute, NIH NCI	CYT-21625: A Novel, Dual-function, Targeted Cancer Nanomedicine	27
Buck, Chris	National Cancer Institute, Center for Cancer Research	Development of a Polyomavirus Vaccine	29
Wu, Jing	Center for Cancer Research, NCI, NIH	Development of [1-13C]-a-KG as an Imaging Probe	35

## From Non-Profit Organizations

Applicant Name	Institution	Project Title	Cycle
Reed, John C.	Sanford-Burnham Institute for Medical Research	Chemical Activators of the PML Tumor Suppressor Pathway	1
Reed, John C.	Sanford-Burnham Institute for Medical Research	Chemical Modulators of Autophagy	1
Sadar, Marianne	BC Cancer Agency/British Columbia Cancer Agency	IND-directed Preclinical Studies of EPI-001 for Prostate Cancer Treatment	3
Laderoute, Keith	SRI International	Estrogen-related Receptor alpha (ERRalpha) Inhibitors as Novel Cancer Therapeutics	4
Wolchok, Jedd	Memorial Sloan-Kettering Cancer Center	Manufacturing of a VRP-TRP2 vaccine for a Phase I Clinical Trial	4
Cravatt, Benjamin	The Scripps Research Institute	Development of Monoacylglycerol-lipase Inhibitors for Cancer Therapy	6
Thottassery, Jaideep	Southern Research Institute	Preclinical Development of T-dCyd: A New Epigenetic Agent	7
Ronai, Ze'ev	Sanford-Burnham Medical Research Institute	Chemical Inducers of ATF2-mediated Apoptotic Activity in Melanoma	9

Diamond, Don	Beckman Research Institute of the City of Hope	CMV Peptide Vaccine to Protect Transplant Recipients Against CMV Infection	11
Hazlehurst, Lori	H. Lee Moffitt Cancer Center & Research Institute	Development of MTI-101 for the Treatment of Relapsed Multiple Myeloma	12
Laderoute, Keith	SRI International (SRI)	5'-AMP-activated Protein Kinase Inhibitors as Novel Cancer Therapeutics	13
Hazlehurst, Lori	H. Lee Moffitt Cancer Center & Research Institute	Development of MTI-101 for the Treatment of Relapsed Multiple Myeloma	16
Federspiel, Mark	Mayo Clinic	Phase 2 Clinical Trial Treating Patients with Refractory Multiple Myeloma W	17
Tautz, Lutz	Sanford Burnham Prebys Medical Discovery Institute	Novel Screen for Allosteric SHP2 Inhibitors	24
Schnitzer, Dr. Jan	Proteogenomics Research Institute for Systems Medicine	Developing hAnnA1-based Immunoconjugates for Cancer Detection and Treatment	25
Cosford, Nicholas	Sanford Burnham Prebys Medical Discovery Institute	Preclinical Development of an ULK1/2 Inhibitor for Pancreatic Cancer	32
Chang, Dr. Long-Sheng	The Research Institute at Nationwide Children's Hospital	Novel eIF4A Inhibitors, Didesmethylocaglamide and Rocaglamide, for Sarcoma	34
D'Andrea, Alan	Dana-Farber Cancer Institute	Novobiocin Treatment of PARP Inhibitor Resistant Cancer	35
Emerling, Brooke	Sanford Burnham Prebys Medical Discovery Institute	Dual PI3P4Ka/β Inhibitors for the Treatment of TP53 Mutant Breast Cancer	37
Lee, John	Fred Hutchinson Cancer Research Center	STEAP1 Chimeric Antigen Receptor T Cell Therapy for Prostate Cancer	38
Nassar, Nicolas	Children's Hospital Medical Center	VAV3 Allosteric Inhibitors for the Treatment of High-Risk Leukemia	38
Zhang, Yeusheng	Health Research Incorporated, Roswell Park Cancer Institute Division	PEPD-G278D for Treatment of HER2-positive Breast Cancer	39

## From Private Sector - Pharmaceutical Companies

Applicant Name	Institution	Project Title	Cycle
Marapaka, Praveen	Medimmune	HA 22 Randomized PIII-HCL	3
Huszar, Dennis	AstraZeneca AB	AZD1480 JAK1/2 Inhibitor	4
Fleming, Ronald	GlaxoSmithKline	GSK2118436 BRAF Inhibitor	5
Levin, Jeremy	GlaxoSmithKline	Oral MEK Inhibitor GSK1120212	6

Huszar, Dennis	AstraZeneca AB	AZD1208 NExT Concept Application	10
Johnson, Lisa	Bristol-Myers Squibb	BMS-936558 Anti-PD-1 Antibody Treatment of Cancer	11
Pluda, James	Merck	Merck & Co., Inc. Agent MK-3475, an Anti-PD1 Monoclonal Antibody (mAb)	11
Watson, Patricia	Merck Sharp & Dohme, Corp.	HDM2; MK-8242 NExT Application	11
Yao, Siu-Long	Merck Sharp & Dohme, Corp.	Vintafolide: MK-8109	12
Wadsworth, Catherine	AstraZeneca	AZD9291 3rd Generation EGFR TKI NeXT Partnership with NCI Application	15
Wagner, Anthony	Amgen Incorporated	AMG 337 NExT Application	15
Healy, Denis	Kyowa Hakko Kirin Pharma, Inc.	Mogamulizumab (a Recombinant, Humanized Monoclonal Antibody)	16
Wadsworth, Catherine	Medimmune	AstraZeneca/MedImmune Cancer Immunotherapy Portfolio NExT Application	16
Woodard, J. Paul	Genentech, Inc.	Genentech MPDL3280A NCI NExT Application 2/15/2014	16
Barry, Simon	AstraZeneca AB	AZD8186 Targeting PI3Kbeta and Delta for Solid and Hematological Tumours	18
Wagner, Anthony	Amgen Incorporated	Talimogene Laherparepvec NExT Application	18
Wagner, Anthony	Amgen Incorporated	AMG 232 NExT Application	19
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Copanlisib, a Pan-Class I PI3K Inhibitor Combination Studies	21
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Anetumab Ravtansine, Novel Mesothelin Directed Drug Conjugate Combo Studies	21
D'Cruz, Celina	AstraZeneca Pharmaceuticals (Waltham)	Savolitinib is a MET Inhibitor with Demonstrated Activity in Solid Tumors	21
Anna, Meg	GlaxoSmithKline	Enhancing Chemo and Targeted Agent Therapy by Combination with a BET Inhib	23
Oh, Choon	GlaxoSmithKline	Application of GSK2816126 (EZH2 Inhibitor) for CTEP Collaboration	23
Faller, Douglas	Millennium Pharmaceuticals Inc	Pevonedistat CRADA	24
McInnes, Campbell	PPI Pharmaceuticals, LLC	Novel non-ATP Competitive Inhibitors of PLK1 that Target Resistant Tumors	24

Noga, Stephen	Millennium Pharmaceuticals Inc	Study of Ixazomib in Select Hematologic and Solid Tumors	24
Senderowicz, Adrian	Cerulean Pharma Inc	Clinical Evaluation of CRLX101 Combinations	24
Ruisi, Mary	EMD Serono, Inc.	M3814 (DNA-PKi) Clinical Research Collaboration	26
Schulz, Mathias	Genentech, Inc.	Venetoclax NeXT Program Application	26
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Rogaratinib (pan-FGFR) Biomarker Directed Clinical Collaboration Proposal	27
Verholen, Frank	Bayer HealthCare Pharmaceuticals	Radium-223 Combination Studies	27
Myles, David	Olema Pharmaceuticals, Inc.	Development of OP-1250, an Oral Complete Antiestrogen	28
Shahidi, Javad	Daiichi Sankyo, Inc.	DS-8201a as Monotherapy or in Combination in Patients with Advanced Solid	28
Amakye, Dereck	Bayer HealthCare Pharmaceuticals	Ataxia Telangiectasia and Rad3-related (ATR) Kinase Inhibitor NExT Proposal	29
Oton, Ana	Eli Lilly and Company	D-cyclin/CDK4 & 6 Dependencies and Drug Combinations Associated with Enhanc	30
Mahadevia, Parthiv	Johnson and Johnson Research and Development, LLC (Raritan)	Erdafitinib NExT Application	31
Semon, Rachel	Advanced Accelerator Applications, a Novartis Company	Advanced Accelerator Applications Proposal	32
Scheller, Libia	Bayer HealthCare Pharmaceuticals	Darolutamide NExT Application Oct 2019	33
Smith, Simon	AstraZeneca (UK)	Clinical Opportunities in Cancer with an ATR Inhibitor, AZD6738	33
Keer, Harold N	Astex Pharmaceuticals, Inc	Oral Hypomethylating Agent for use in Combination Therapy	34
Ngarmchamnanrith, Gift	Amgen Incorporated	AMG 510 Proposal	34
Fellous, Marc	Bayer HealthCare Pharmaceuticals	Larotrectinib (Vitrakvi): NTRK Inhibitor	36
Kamboj, Raj	Lupin Limited	LNP7457: A Novel PRMT5 Inhibitor for Solid Tumors and Hematological Cancers	36
Sommavilla, Roberto	AstraZeneca (UK)	Expanding the Investigation of Capivasertib in Haematology & Solid Tumours	36
Gharibo, Mecide	Bristol-Myers Squibb Company	BMS NExT Submission - iberdomide (CELMoD)	38

Gounaris, Ioannis	Merck KGaA	Oral ATR Inhibitor M1774 Development	38
Gray, Kathleen	Janssen Pharmaceutical Companies of Johnson & Johnson	NExT Application for Teclistamab CRADA	38
Shah, Jatin	Karyopharm Therapeutics, Inc.	Eltanexor for Unmet Needs in Myeloid Malignancies and ALL	39
* Top Tier applications are not guaranteed to be accepted into the NExT Program			

Feb. 2022